Tags : Novo Nordisk

Novo Nordisk Collaborates with Noom to Provide Digital Health Solutions

Shots: The companies collaborate on digital health solutions focusing on weight management and education with the goal of improving the lives of patients living with obesity The collaboration follows 8mos. pilot study which united Noom’s science-backed behavior change programs with Novo Nordisk’s 95yrs.+ experience will help to educate people with obesity to lose weight and […]Read More

PharmaShots Weekly Snapshot (September 23– 27, 2019)

1. Incyte Reports Updated Results of Pemigatinib in P-II FIGHT-202 Trial for Patients with Previously Treated Advanced Cholangiocarcinoma Published: Sept 27, 2019 | Tags: Incyte, Reports, Updated, Results, Pemigatinib, P-II, FIGHT-202 Trial, Patients, Previously, Treated, Advanced, Cholangiocarcinoma 2.Pfizer Reports Results of Abrocitinib in P-III JADE MONO-2 Study for Moderate to Severe Atopic Dermatitis Published: Sept 27, 2019 […]Read More

Top 20 Biopharma Acquisitions of 2018 Based on the Total

Biopharma acquisition activity in 2018 shows a significant increase over the previous year. Takeda proved to be on top with the acquisition of Shire among the top 20 acquisitions with a total deal value of $57.17B strengthening its capabilities in gastroenterology, neuroscience, oncology, rare diseases, and plasma-derived therapies. This article is based on the 2018 […]Read More

PharmaShots Weekly Snapshot (September 16– 20, 2019)

1.Boehringer Ingelheim Enters into an Agreement with Inflammasome Therapeutics to Co-Develop Therapies for Retinal Diseases Published: Sept 20, 2019 | Tags: Boehringer Ingelheim, Agreement, Inflammasome Therapeutics, Co-Develop, Therapies, Retinal Disease 2. Astellas and FibroGen’s Evrenzo (roxadustat) Receives MHLW’s Approval for Anemia Associated with Chronic Kidney Disease in Dialysis Patients Published: Sept 20, 2019 | Tags: Astellas, FibroGen, […]Read More

Novo Nordisk Reports Results of Tresiba (insulin degludec) in CONCLUDE

Shots: The CONCLUDE study assess the hypoglycemic risk with Tresiba (qd) vs insulin glargine U300 (qd) in 1,609 patients with T2D with/out oral anti-diabetic drugs, for 36wks. maintenance period and a total treatment period of up to 88wks. The CONCLUDE study result: reduction in the rate of severe hypoglycemia & nocturnal symptomatic hypoglycemia (80% & […]Read More

Medtronic and Novo Nordisk Collaborate to Deliver Integrated Digital Solutions

Shots: The companies collaborated to develop solutions to integrate insulin dosing data utilizing upcoming Novo Nordisk’s insulin pens in Medtronic’s Guardian Connect system The integration of glucose monitoring and insulin dosing data, allow patients and healthcare professionals to automatically track glucose level and insulin dose for better managing glucose levels and increasing Time in Range […]Read More

Novo Nordisk Reports Results of Refixia (nonacog beta pegol) in

Shots: The two P-III studies include Paradigm5 & 6. Paradigm5 involves assessing of Refixia (40 IU/kg, qw) in 25 children with hemophilia B aged ≤12 yrs. resulted in low bleeding rates with 20% bleed free patients and 64% with no spontaneous bleeds. No children developed inhibitory Ab & no new safety signals are observed The […]Read More

Novo Nordisk’s Esperoct (turoctocog alfa pegol, N8-GP) Receives European Commission

Shots: The approval is based on results from pre-registration clinical programme assessing Esperoct in 270 patients with severe hemophilia A with 5+years of clinical exposure. The authorization covers all 28 European Union member states The marketing authorization follows EMA’s CHMP positive opinion granted on Apr 26, 2019 with its expected launch in European countries in […]Read More

Insights+: An Analysis of Biopharma Companies Growth in Last 20

In the last 20 years the global Biopharma space has changed a lot with ups and downs of companies and their growth. This analysis has found the multiple acquisitions and mergers along with the launch of several blockbusters leading to jump in growth and revenue of numerous companies. Pfizer acquired Warner-Lambert in 2000 to gain […]Read More